Provides drug discovery tools to biopharmaceutical companies. Offers biological models for drug discovery. Now — the numbers.
This is an established company with proven profits.
An average decline of 28% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $2K. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 29% — still a thick cushion, though costs have been eating into it lately.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 5 years, sales fell about 28% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.